Eli Lilly (LLY) Change in Intangibles (2010 - 2024)
Eli Lilly (LLY) reported Change in Intangibles of $70.1 million for Q4 2024, up 23466.67% on a YoY basis from N/an in Q1 2024, and up 23466.67% quarter-over-quarter from -$300000.0 in Q4 2023.
Eli Lilly (LLY) Change in Intangibles (2010 - 2024) Analysis & Trends
Eli Lilly has reported Change in Intangibles for 8 years, with the latest figure at $70.1 million in Q4 2024.
- For the quarter ending Q4 2024, Change in Intangibles rose 23466.67% year-over-year to $70.1 million; the trailing twelve-month figure through Dec 2024 stood at $599.8 million (up 13.21% YoY), and the FY2025 full-year result was $218.0 million, down 63.73% from the prior year.
- Change in Intangibles for Q4 2024 stood at $70.1 million, up from -$300000.0 in the prior quarter.
- The five-year high for Change in Intangibles was $500.0 million in Q2 2023, with the low at -$300000.0 in Q4 2023.
- Historically, Change in Intangibles has averaged $150.0 million across 3 years, with a median of $50.0 million in 2022.
- Annual changes were most pronounced in 2023 — Change in Intangibles plunged 101.0% — and 2024, when it soared 23466.67%.
- Eli Lilly's Change in Intangibles stood at $30.0 million in 2022, then slumped by 101.0% to -$300000.0 in 2023, then soared by 23466.67% to $70.1 million in 2024.
- The last three Change in Intangibles figures came in at $70.1 million (Q4 2024), -$300000.0 (Q4 2023), and $500.0 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -299.30 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -461.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 70.10 Mn |
| Dec 31, 2024 | 70.10 Mn |
| Dec 31, 2023 | -300,000.00 |
| Dec 31, 2023 | -300,000.00 |
| Jun 30, 2023 | 500.00 Mn |
| Jun 30, 2023 | 500.00 Mn |
| Dec 31, 2022 | 30.00 Mn |
| Dec 31, 2022 | 30.00 Mn |
| Dec 31, 2014 | 100,000.00 |
| Dec 31, 2014 | 100,000.00 |
| Sep 30, 2014 | 236.90 Mn |
| Sep 30, 2014 | 236.90 Mn |
| Jun 30, 2014 | 46.30 Mn |
| Jun 30, 2014 | 46.30 Mn |
| Mar 31, 2014 | 25.00 Mn |
| Mar 31, 2014 | 25.00 Mn |
| Dec 31, 2013 | 24.10 Mn |
| Dec 31, 2013 | 24.10 Mn |
| Jun 30, 2012 | 34.30 Mn |
| Jun 30, 2012 | 34.30 Mn |